F2R and coronary artery disorder: On top of standard antiplatelet therapy, vorapaxar reduces the risk of ischemic events or cardiovascular death in patients with stable coronary artery disease (CAD).1Vorapaxar is a selective antagonist of protease-activated receptor-1 (PAR-1), thereby blocking thrombin-mediated platelet activation.2, 3However, other actions of thrombin, such as fibrin formation and protein-C activation, are not inhibited by blocking PAR-1.